Status:
COMPLETED
Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
Lead Sponsor:
Pfizer
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
18+ years
Brief Summary
This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital r...
Eligibility Criteria
Inclusion
- Diagnosed AS patients.
- 18 years old
- Did not receive previous biological treatment for any reason
Exclusion
- Patients previously or currently treated with other biological therapies.
- Use of etanercept for less than 1 year duration.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
763 Patients enrolled
Trial Details
Trial ID
NCT04507763
Start Date
August 1 2020
End Date
October 1 2020
Last Update
October 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Baghdad, Iraq